CAS: 1625-91-8; 4,4'-Di-Tert-Butyl-1,1'-Biphenyl

相似化合物

1625-92-9 162258-89-1 18970-30-4

上下游产品

biphenyl 2-methyl-propan-1-ol 1-tert-butyl-4-iodobenzene tert-butylbenzene 4,4'-di-tert-butyl-2-nitrobiphenyl 2,2′-dibromo-4,4′-di-tert-butylbiphenyl 3-(4-tert-Butylphenyl)-3,6,6-trimethoxycyclohexa-1,4-diene 2,7-di-tert-butylfluorenone

4-Tert-Butylphenyl Triflate置于(1,1'-双(二苯基膦)二茂铁)二氯化镍,Potassium Iodide,锌体系中,用 N,N-二甲基甲酰胺 用作溶剂,化学反应 6.0H,以36%的收率获得4,4'-二叔丁基苯并
参考文献:镍和钯催化的芳基三氟甲磺酸同质偶合.范围,局限性和机制方面.
标题:镍和钯催化的芳基三氟甲磺酸同质偶合.范围,局限性和机制方面.
摘要:芳基三氟甲磺酸酯的直接还原主要提供酚和一些芳烃,而催化量的钯或镍的存在导致联芳基的形成.均相耦合在电子源(阴极或锌粉)的存在下进行.对金属(镍或钯),配体(单齿或双齿膦)和还原过程(电化学或化学)的明智选择可以合成功能对称的联芳基.由二齿配体如nicl(2)(dppf)和pd(oac)(2)+1 Binap连接的镍和钯配合物对于1-萘基三氟甲磺酸酯的均偶联非常有效,因为二聚体几乎以定量获得.但是,均一耦合对空间位阻敏感,目前不包括阻转异构体的合成.
Doi:10.1021/jo961464B

专利信息

专利号:US-6350878-B1
优先权日:1998-05-18
标 题 :Intermediates for the synthesis of epothilones and methods for their preparation
发明人：ALTMANN KARL-HEINZ; BAUER ARMIN; SCHINZER DIETER
权利人:NOVARTIS AG
摘要:The invention relates to a method of synthesis for a compound of formula (I),wherein R is a heterocyclyl moiety and X1, X2, X3 and X4 are, independently of each other, protecting groups, which is appropriate for the synthesis of epothilone B and desoxyepothione B.

专利号:US-6388128-B1
优先权日:1998-10-05
标 题:Stannane synthesis of prostanoids
发明人：CONROW RAYMOND E
权利人:ALCON MFG LTD
摘要:The present invention is directed to novel methods of prostanoid synthesis. Specifically, the invention is directed to the addition of alpha chains to prostanoids using cis-alkenylstannane intermediates.

专利号:US-5710320-A
优先权日:1994-07-21
标题:Diaryliodonium fluoroalkyl sulfonate salts and a method of making
发明人：VOGEL DENNIS E; VOGEL KIM M
权利人:MINNESOTA MINING & MFG
摘要:The present invention provides a convenient, simple, safe and efficient one-pot method for the synthesis of a number of diarlyiodonium triflate salts which does not involve sulfuric acid and which eliminates the need for any counter-ion exchange processes. n The invention also provides a novel salt of the formula ##STR1##

专利号:US-9683010-B2
优先权日:2014-02-17
标 题 :Process for the production of 21-methoxy-11-beta-phenyl-19-nor-pregna-4,9-diene-3,20-dione derivatives
发明人：Mahó Sándor; SÃ?NTA CSABA; Csörgei János; Szabó Gábor; SCHÄFER TAMÃ?S; BÉNI ZOLTÃ?N
权利人:RICHTER GEDEON NYRT
摘要:The present invention relates to a process for the synthesis of compounds of formula (I), n nwherein the meaning of R is dimethylamino or acetyl group, using the compound of formula (III) or (IV), wherein the meaning of R′ is dimethylamino or 2-methyl-1,3-dioxan-2-yl group, as starting material and methoxymethyl lithium as reagent.

专利号:US-5478959-A
优先权日:1994-10-05
标题:Method for preparing 1,2-dithiins and precursors of 1,2-dithiins
发明人：BLOCK ERIC; GUO CHUANGXING
权利人:UNIV NEW YORK STATE RES FOUND
摘要:A method for preparing 1,4-(Z,Z)-disubstituted-1,4-disulfurated-1,3-butadienes is disclosed. The butadienes can be further elaborated to provide 3,6-unsymmetrically-substituted-1,2-dithiins. Also disclosed are butadienes prepared by the method of the invention. These butadienes are useful as intermediates in the synthesis of antibiotic 1,2-dithiins.

专利号:US-7612106-B2
优先权日:2004-12-23
标题 :Fused pyrazole derivatives and methods of treatment of metabolic-related disorders thereof
发明人：BOATMAN P DOUGLAS; SCHRADER THOMAS O; SEMPLE GRAEME; SKINNER PHILIP J; JUNG JAE-KYU
权利人:ARENA PHARM INC
摘要:The present invention relates to certain fused pyrazole derivatives of Formula (Ia), and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists for the RUP25 receptor. n nAlso provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance, type 2 diabetes, Syndrome-X and the like. In addition, the present invention also provides for the use of the compounds of the invention in combination with other active agents such as those belonging to the class of α-glucosidase inhibitors, aldose reductase inhibitors, biguanides, HMG-CoA reductase inhibitors, squalene synthesis inhibitors, fibrates, LDL catabolism enhancers, angiotensin converting enzyme (ACE) inhibitors, insulin secretion enhancers, DP receptor antagonists, and the like.